ICON Public Limited (NASDAQ:ICLR) Shares Sold by Entropy Technologies LP

Entropy Technologies LP reduced its stake in ICON Public Limited (NASDAQ:ICLR - Free Report) by 78.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,079 shares of the medical research company's stock after selling 3,899 shares during the quarter. Entropy Technologies LP's holdings in ICON Public were worth $310,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. SkyView Investment Advisors LLC purchased a new position in ICON Public during the 1st quarter valued at about $1,021,000. EverSource Wealth Advisors LLC grew its holdings in shares of ICON Public by 17.4% in the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company's stock valued at $95,000 after purchasing an additional 42 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of ICON Public by 50.0% in the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company's stock valued at $82,000 after purchasing an additional 87 shares in the last quarter. ORG Partners LLC purchased a new stake in ICON Public during the 2nd quarter worth approximately $59,000. Finally, Liontrust Investment Partners LLP boosted its position in ICON Public by 19.5% in the 2nd quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company's stock valued at $37,531,000 after buying an additional 19,546 shares during the period. Hedge funds and other institutional investors own 95.61% of the company's stock.

Wall Street Analyst Weigh In

ICLR has been the topic of several analyst reports. Leerink Partnrs upgraded ICON Public to a "strong-buy" rating in a research note on Wednesday, September 18th. The Goldman Sachs Group reduced their price target on ICON Public from $370.00 to $280.00 and set a "buy" rating on the stock in a research report on Friday, October 25th. Baird R W downgraded ICON Public from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 24th. Evercore ISI reduced their target price on shares of ICON Public from $360.00 to $350.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. lowered their price target on shares of ICON Public from $375.00 to $280.00 and set an "overweight" rating for the company in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ICON Public has a consensus rating of "Moderate Buy" and a consensus price target of $304.27.

ICON Public Stock Down 5.2 %

NASDAQ:ICLR traded down $10.38 during midday trading on Friday, hitting $189.64. 2,203,578 shares of the company were exchanged, compared to its average volume of 1,969,235. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public Limited has a fifty-two week low of $188.57 and a fifty-two week high of $347.72. The company has a market capitalization of $15.65 billion, a PE ratio of 21.14, a price-to-earnings-growth ratio of 1.40 and a beta of 1.25. The company has a fifty day simple moving average of $267.03 and a 200 day simple moving average of $301.32.

ICON Public (NASDAQ:ICLR - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analysts' expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm posted $3.10 earnings per share. As a group, equities analysts anticipate that ICON Public Limited will post 13.43 earnings per share for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.